These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35239184)

  • 21. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
    Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
    Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic Modulation of Radiation-Induced Diacylglycerol Kinase Alpha Expression Prevents Pro-Fibrotic Fibroblast Response.
    Liu CS; Toth R; Bakr A; Goyal A; Islam MS; Breuer K; Mayakonda A; Lin YY; Stepper P; Jurkowski TP; Veldwijk MR; Sperk E; Herskind C; Lutsik P; Weichenhan D; Plass C; Schmezer P; Popanda O
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34070078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
    Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
    Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.
    Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW
    Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
    Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
    Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and Synthesis of a Highly Selective and
    Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
    Aylott HE; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Seal JT; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Mar; 64(6):3249-3281. PubMed ID: 33662213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility.
    Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M
    Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.
    Bai P; Yan L; Bagdasarian FA; Wilks MQ; Wey HY; Wang C
    Chem Commun (Camb); 2022 Aug; 58(69):9654-9657. PubMed ID: 35943085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding selectivity of inhibitors toward the first over the second bromodomain of BRD4: theoretical insights from free energy calculations and multiple short molecular dynamics simulations.
    Wang Y; Wu S; Wang L; Yang Z; Zhao J; Zhang L
    RSC Adv; 2020 Dec; 11(2):745-759. PubMed ID: 35423696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
    Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
    J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.